Novartis & W.K. Buckley
This article was originally published in The Tan Sheet
Novartis is "currently evaluating the opportunity of expanding" Buckley's cough/cold line in U.S. in wake of marketing, distribution deal between the two companies. Toronto-based firm's top-selling Buckley's Mixture cough syrup trades on its "tastes awful and it works" claim and has been sold in U.S. since 1930s; firm launched a $2.1 mil. North American ad campaign three years ago (1"The Tan Sheet" Aug. 16, 1999, p. 5). Buckley's line rounds out Novartis' Canadian cough/cold offerings, which include Triaminic syrups for children, NeoCitran hot liquid powder, Otrivin nasal spray. Companies announced "innovative" agreement Nov. 15 that provides Novartis with "exclusive and indefinite rights to sales, marketing and distribution of Buckley's products throughout the world," according to Novartis...
You may also be interested in...
W.K. Buckley, the Canadian cough syrup maker, is breaking a $2.1 mil. North American advertising campaign in November. The ads for the 80-year-old Buckley's Mixture Cough Suppressant liquid will continue to use the firm's trademark tagline, "It tastes awful. And it works," highlighting the product's bad taste as part and parcel of its effectiveness.
3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.